

Keiran S M Smalley

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4369337/keiran-s-m-smalley-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

13,728
citations

54
h-index

115
g-index

192
ext. papers

15,463
ext. citations

7.7
avg, IF

6.17
L-index

#	Paper	IF	Citations
162	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
161	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3041-6	11.5	1056
160	PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. <i>Cancer Research</i> , 2011 , 71, 2750-60	10.1	419
159	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1136-44	6.1	372
158	A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. <i>International Journal of Cancer</i> , 2003 , 104, 527-32	7.5	286
157	Adhesion, migration and communication in melanocytes and melanoma. <i>Pigment Cell & Melanoma Research</i> , 2005 , 18, 150-9		251
156	Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2876-83	6.1	246
155	Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. <i>British Journal of Cancer</i> , 2010 , 102, 1724-30	8.7	242
154	Rewired ERK-JNK signaling pathways in melanoma. <i>Cancer Cell</i> , 2007 , 11, 447-60	24.3	240
153	Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. <i>Cancer Research</i> , 2006 , 66, 11100-5	10.1	229
152	Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. <i>Cancer Research</i> , 2006 , 66, 4182-90	10.1	228
151	Life isn't flat: taking cancer biology to the next dimension. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2006 , 42, 242-7	2.6	223
150	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. <i>Frontiers in Bioscience - Landmark</i> , 2005 , 10, 2986-3001	2.8	208
149	An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. <i>Cancer Research</i> , 2007 , 67, 209-17	10.1	207
148	The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. <i>Clinical Cancer Research</i> , 2008 , 14, 230-9	12.9	197
147	CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. <i>Oncogene</i> , 2009 , 28, 85-94	9.2	170
146	Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 390-9	19.4	140

145	Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. <i>Biochemical Pharmacology</i> , 2011 , 82, 201-9	6	136
144	The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. <i>Clinical Cancer Research</i> , 2012 , 18, 2502-14	12.9	130
143	The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. <i>FEBS Letters</i> , 2000 , 476, 198-202	3.8	128
142	PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. <i>Pigment Cell and Melanoma Research</i> , 2010 , 23, 820-7	4.5	122
141	Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. <i>American Journal of Pathology</i> , 2005 , 166, 1541-54	5.8	122
140	The role of altered cell-cell communication in melanoma progression. <i>Journal of Molecular Histology</i> , 2004 , 35, 309-18	3.3	116
139	Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. <i>American Journal of Pathology</i> , 2007 , 170, 709-21	5.8	106
138	Fibroblast-mediated drug resistance in cancer. <i>Biochemical Pharmacology</i> , 2013 , 85, 1033-41	6	105
137	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. <i>Oncogene</i> , 2013 , 32, 3009-18	9.2	99
136	Understanding melanoma signaling networks as the basis for molecular targeted therapy. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 28-37	4.3	98
135	Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. <i>Science Signaling</i> , 2013 , 6, ra7	8.8	96
134	The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. <i>Gastroenterology</i> , 2008 , 134, 1981-93	13.3	96
133	Defining the conditions for the generation of melanocytes from human embryonic stem cells. <i>Stem Cells</i> , 2006 , 24, 1668-77	5.8	95
132	Fibroblasts contribute to melanoma tumor growth and drug resistance. <i>Molecular Pharmaceutics</i> , 2011 , 8, 2039-49	5.6	90
131	Essential role of HDAC6 in the regulation of PD-L1 in melanoma. <i>Molecular Oncology</i> , 2016 , 10, 735-750	7.9	89
130	The treatment of advanced renal cell cancer with high-dose oral thalidomide. <i>British Journal of Cancer</i> , 2001 , 85, 953-8	8.7	89
129	Beyond BRAF: where next for melanoma therapy?. <i>British Journal of Cancer</i> , 2015 , 112, 217-26	8.7	87
128	In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2008 , 3, 1-10	6.2	83

127	Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. <i>Molecular Oncology</i> , 2015 , 9, 1447-1457	7.9	82
126	Similar biological activities of two isostructural ruthenium and osmium complexes. <i>Chemistry - A European Journal</i> , 2008 , 14, 4816-22	4.8	81
125	Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. <i>Cancer Research</i> , 2008 , 68, 5743-52	10.1	79
124	Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. <i>British Journal of Cancer</i> , 2007 , 96, 445-9	8.7	78
123	Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. <i>International Journal of Cancer</i> , 2003 , 105, 165-75	7.5	78
122	Integrating BRAF/MEK inhibitors into combination therapy for melanoma. <i>British Journal of Cancer</i> , 2009 , 100, 431-5	8.7	73
121	A brief history of melanoma: from mummies to mutations. <i>Melanoma Research</i> , 2012 , 22, 114-22	3.3	73
120	Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2793-2804	6.1	70
119	Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1059, 16-25	6.5	68
118	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 404-16	4.5	63
117	Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. <i>Cancer Discovery</i> , 2015 , 5, 264-73	24.4	61
116	BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 3115-3124	4.3	61
115	Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. <i>Cancer Research</i> , 2009 , 69, 3241-4	10.1	60
114	Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. <i>Cancer Journal (Sudbury, Mass.)</i> , 2012 , 18, 124-31	2.2	60
113	Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. <i>Cancer</i> , 2018 , 124, 297-305	6.4	59
112	Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2866-75	6.1	58
111	Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. <i>Oncogene</i> , 2016 , 35, 1225-35	9.2	56
110	Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. <i>Oncogene</i> , 2017 , 36, 1849-1861	9.2	54

109	c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. <i>Histology and Histopathology</i> , 2009 , 24, 643-50	1.4	54
108	Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. <i>Clinical Cancer Research</i> , 2014 , 20, 4186-92	12.9	49
107	Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. <i>ACS Chemical Biology</i> , 2008 , 3, 305-16	4.9	49
106	Selective evolutionary pressure from the tissue microenvironment drives tumor progression. <i>Seminars in Cancer Biology</i> , 2005 , 15, 451-9	12.7	48
105	The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. <i>PLoS ONE</i> , 2013 , 8, e59588	3.7	48
104	Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. <i>International Journal of Cancer</i> , 2002 , 98, 514-22	7.5	45
103	Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. <i>Molecular and Cellular Proteomics</i> , 2014 , 13, 1844-54	7.6	44
102	Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 465-78	4.5	43
101	Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 901-12	6.1	43
100	A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. <i>Proteomics - Clinical Applications</i> , 2011 , 5, 383-96	3.1	43
99	HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 5686-5701	12.9	42
98	Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 1154-8	4.5	40
97	PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. <i>Current Opinion in Investigational Drugs</i> , 2010 , 11, 699-706		38
96	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. <i>Cancer Research</i> , 2019 , 79, 2947-2961	10.1	37
95	Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5516-5524	12.9	37
94	Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach. <i>Cancer Research</i> , 2013 , 73, 6874-85	10.1	35
93	Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin. <i>Tissue Engineering - Part A</i> , 2014 , 20, 2412-21	3.9	32
92	The pivotal role of phosphoinositide-3 kinase in the human somatostatin sst(4) receptor-mediated stimulation of p44/p42 mitogen-activated protein kinase and extracellular acidification. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 263, 239-43	3.4	31

91	ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?. <i>Cancer Discovery</i> , 2018 , 8, 140-142	24.4	30
90	GSK3 β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 2818-27	4.3	30
89	An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance. <i>Cancer Discovery</i> , 2013 , 3, 260-3	24.4	30
88	Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. <i>Melanoma Research</i> , 2002 , 12, 187-92	3.3	30
87	Melanoma Biomarkers. <i>Molecular Diagnosis and Therapy</i> , 2009 , 13, 283-296	4.5	29
86	Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. <i>EBioMedicine</i> , 2019 , 48, 178-190	8.8	28
85	Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. <i>International Journal of Cancer</i> , 2016 , 139, 1195-201	7.5	28
84	K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. <i>Nature Communications</i> , 2019 , 10, 1870	17.4	26
83	The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. <i>Biochemical Pharmacology</i> , 2016 , 122, 1-9	6	25
82	Resistance to Raf inhibition in cancer. <i>Drug Discovery Today: Technologies</i> , 2014 , 11, 27-32	7.1	24
81	The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1354-64	6.1	23
80	Phase i trials in melanoma: A framework to translate preclinical findings to the clinic. <i>European Journal of Cancer</i> , 2016 , 67, 213-222	7.5	23
79	The current state of targeted therapy in melanoma: this time it's personal. <i>Seminars in Oncology</i> , 2012 , 39, 204-14	5.5	22
78	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017 , 23, 6203-6214	12.9	22
77	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 527-541	4.5	21
76	Differential agonist activity of somatostatin and L-362855 at human recombinant sst4 receptors. <i>British Journal of Pharmacology</i> , 1998 , 125, 833-41	8.6	21
75	Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. <i>Clinical Cancer Research</i> , 2013 , 19, 6329-30	12.9	20
74	Towards the targeted therapy of melanoma. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006 , 6, 387-93	3.2	20

73	Targeted therapy in melanoma. <i>Clinics in Dermatology</i> , 2013 , 31, 200-8	3	19
72	Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance. <i>Clinical Cancer Research</i> , 2020 , 26, 2163-2175	12.9	19
71	BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. <i>Melanoma Research</i> , 2016 , 26, 83-7	3.3	18
70	Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. <i>Future Oncology</i> , 2009 , 5, 775-8	3.6	17
69	Targeting the stromal fibroblasts: a novel approach to melanoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 1069-78	3.5	17
68	Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. <i>Oncotarget</i> , 2011 , 2, 329-35	3.3	17
67	Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology. <i>Survey of Ophthalmology</i> , 2019 , 64, 272-288	6.1	17
66	Melanoma genotypes and phenotypes get personal. <i>Laboratory Investigation</i> , 2013 , 93, 858-67	5.9	16
65	Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1218-26	6.1	16
64	Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells. <i>Pharmacological Research</i> , 2017 , 119, 242-250	10.2	15
63	Combination Therapies for Melanoma: A New Standard of Care?. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 99-105	7.1	15
62	Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis?. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 711-4	3.5	15
61	Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. <i>Biochemical Pharmacology</i> , 2010 , 80, 739-47	6	15
60	Ligand internalization and recycling by human recombinant somatostatin type 4 (h sst(4)) receptors expressed in CHO-K1 cells. <i>British Journal of Pharmacology</i> , 2001 , 132, 1102-10	8.6	15
59	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2019 , 32, 458-469	4.5	15
58	Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. <i>Molecular Oncology</i> , 2018 , 12, 74-88	7.9	15
57	Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. <i>International Journal of Cancer</i> , 2009 , 124, 1245-50	7.5	14
56	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021 , 27, 4109-4125	12.9	14

55	Why do women with melanoma do better than men?. <i>ELife</i> , 2018 , 7,	8.9	14
54	Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. <i>Journal of Proteome Research</i> , 2016 , 15, 4476-4489	5.6	13
53	Decitabine limits escape from MEK inhibition in uveal melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 507-514	4.5	13
52	Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. <i>Proteomics</i> , 2015 , 15, 327-39	4.8	12
51	Novel treatments for melanoma brain metastases. <i>Cancer Control</i> , 2013 , 20, 298-306	2.2	12
50	Ceritinib Enhances the Efficacy of Trametinib in -Wild-Type Melanoma Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 73-83	6.1	12
49	The complexity of microenvironment-mediated drug resistance. <i>Genes and Cancer</i> , 2015 , 6, 367-8	2.9	11
48	Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. <i>Molecular Diagnosis and Therapy</i> , 2009 , 13, 283-96	4.5	11
47	In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. <i>Molecular Pharmaceutics</i> , 2013 , 10, 3175-85	5.6	10
46	Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. <i>Melanoma Research</i> , 2014 , 24, 448-53	3.3	10
45	Targeted therapy for melanoma: is double hitting a home run?. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 5-6	19.4	10
44	Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines. <i>Methods in Enzymology</i> , 2010 , 484, 549-67	1.7	10
43	Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report. <i>Pigment Cell and Melanoma Research</i> , 2009 , 22, 386-7	4.5	10
42	Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. <i>Journal of Investigative Dermatology</i> , 2004 , 123, xvi-xvii	4.3	10
41	Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. <i>Methods</i> , 2015 , 81, 41-9	4.6	9
40	XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2542-2544	4.3	9
39	Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance. <i>Cancer Discovery</i> , 2012 , 2, 390-2	24.4	9
38	ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcatechol (4-NC). <i>Pharmacological Research</i> , 2019 , 141, 63-72	10.2	9

37	Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. <i>Biochemical Pharmacology</i> , 2014 , 91, 417-25	6	8
36	Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies. <i>Cancer Control</i> , 2017 , 24, 42-46	2.2	8
35	Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. <i>Pigment Cell and Melanoma Research</i> , 2009 , 22, 529-31	4.5	8
34	Frontiers in pigment cell and melanoma research. <i>Pigment Cell and Melanoma Research</i> , 2018 , 31, 728-735	4.5	8
33	SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer. <i>Bioinformatics</i> , 2017 , 33, 2951-2953	7.2	7
32	Inhibition of BRAF and MEK in BRAF-mutant melanoma. <i>Lancet, The</i> , 2015 , 386, 410-2	4.0	7
31	The biology and therapeutic management of melanoma brain metastases. <i>Biochemical Pharmacology</i> , 2018 , 153, 35-45	6	7
30	Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma. <i>Experimental Dermatology</i> , 2015 , 24, 657-8	4	7
29	Translational pathology, genomics and the development of systemic therapies for acral melanoma. <i>Seminars in Cancer Biology</i> , 2020 , 61, 149-157	12.7	7
28	Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor-Resistant Melanoma. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 840-851.e4	4.3	7
27	A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. <i>Melanoma Research</i> , 2016 , 26, 481-6	3.3	5
26	Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses. <i>Cancer Discovery</i> , 2020 , 10, 176-178	24.4	5
25	Improving patient outcomes to targeted therapies in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 633-41	3.5	5
24	Get with the Program! Stemness and Reprogramming in Melanoma Metastasis. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 10-13	4.3	4
23	Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. <i>Melanoma Research</i> , 2017 , 27, 545-557	3.3	4
22	MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer. <i>Cancer Research</i> , 2019 , 79, 5812-5825	10.1	3
21	BRAF-MEK inhibition in melanoma brain metastases: a new hope. <i>Lancet Oncology, The</i> , 2017 , 18, 836-837	1.7	3
20	Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma. <i>Molecular and Cellular Oncology</i> , 2015 , 2, e1008291	1.2	3

19	MEK-ing the Most of It: Strategies to Co-target G β and MAPK in Uveal Melanoma. <i>Clinical Cancer Research</i> , 2021 , 27, 1217-1219	12.9	3
18	Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021 , 9, 554-567	12.5	3
17	Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9544-9544	2.2	2
16	A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease. <i>Journal of Visualized Experiments</i> , 2021 ,	1.6	2
15	Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma. <i>Journal of Investigative Dermatology</i> , 2021 ,	4.3	2
14	Mutant BRAF: a novel mediator of microenvironmental escape in melanoma?. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1135-7	4.3	1
13	The future of targeted therapy approaches in melanoma. <i>Expert Opinion on Drug Discovery</i> , 2009 , 4, 445-56		1
12	Is ERK activation a good biomarker for estradiol and tamoxifen effects?. <i>Cancer Biology and Therapy</i> , 2007 , 6, 119-20	4.6	1
11	A Mutational Survey of Acral Nevi. <i>JAMA Dermatology</i> , 2021 , 157, 831-835	5.1	1
10	Melanoma brain metastases: Biological basis and novel therapeutic strategies. <i>Experimental Dermatology</i> , 2021 ,	4	1
9	EXTH-39. DETECTION, MOLECULAR PROFILING AND CULTURE OF CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) IN MELANOMA TO IMPROVE DIAGNOSIS AND TREATMENT STRATEGIES. <i>Neuro-Oncology</i> , 2018 , 20, vi93-vi93	1	1
8	Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. <i>Cancer</i> , 2018 , 124, 2254-2255	6.4	
7	Somatic genetics and targeted therapies for cutaneous melanoma. <i>Update on Cancer Therapeutics</i> , 2008 , 3, 81-87		
6	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. <i>Expert Review of Dermatology</i> , 2007 , 2, 179-190		
5	Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9062-9062	2.2	
4	Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy. <i>Cancer Drug Discovery and Development</i> , 2015 , 137-162	0.3	
3	Therapeutic Targeting of the Melanoma Stem Cell Population. <i>Translational Medicine Series</i> , 2008 , 83-98		
2	Targeting BRAF Activity as a Novel Paradigm for Melanoma Therapy. <i>Translational Medicine Series</i> , 2008 , 67-82		

- 1 Melanoma and Other Skin Cancers **2012**, 439-468